Resurrection of Thallium-201 for Myocardial Perfusion Imaging⁎⁎Editorials published in JACC: Cardiovascular Imaging reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Imaging or the American College of Cardiology.  by Strauss, H. William & Bailey, Dale
J A C C : C A R D I O V A S C U L A R I M A G I N G V O L . 2 , N O . 3 , 2 0 0 9
© 2 0 0 9 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 8 X / 0 9 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . D O I : 1 0 . 1 0 1 6 / j . j c m g . 2 0 0 9 . 0 1 . 0 0 2E D I T O R I A L C O M M E N T
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iThallium-201 has several virtues as a myocardial
perfusion agent. It is one of the best of the soluble
agents for measuring regional myocardial perfusion,
because it has a blood clearance half-time of 30 s
and a first pass extraction in the myocardium of
88% (1) (compared with the1-min blood clear-
ance half-time [2] and 50% to 60% first pass
extraction of technetium-99m sestamibi) (3). These
biological characteristics of thallium provide higher
contrast between regions of normal perfusion and
zones of ischemia, even on planar myocardial perfu-
sion studies. Numerous publications confirmed the
sensitivity, specificity, and diagnostic accuracy of myo-
cardial perfusion imaging with thallium (4,5).
See page 273
Some biological characteristics of thallium, how-
ever, are not so favorable. The electron capture
decay of thallium produces 88 X-ray photons at 70
to 80 keV and approximately 12 gamma photons at
135 and 167 keV for each 100 disintegrations. In
addition to the low energy of the predominant
photon, the physical half-life of 73 h and biological
half-life of approximately 10 days (240 h) results in
a relatively long effective half-life of approximately
56 h. In addition to myocardium, skeletal muscle,
and liver—the tracer also localizes—in the testes
and kidneys, producing an effective dose equivalent
of 34.5 mSv/150 MBq (6). The result is a limitation
of the administered dose to approximately 150
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When technetium-99m–labeled sestamibi was
pproved by the Food and Drug Administration in
ecember 1991 (7), there was rapid adoption of the
racer, even though it was inferior to thallium for
he determination of regional myocardial perfusion.
uman studies demonstrated reduced lesion size
ith stress sestamibi imaging compared with thal-
ium, making regions of mild ischemia more diffi-
ult to identify on myocardial perfusion scans (8).
his property of reduced contrast is also shared by
etrofosmin. In spite of longer blood clearance and
ower myocardial extraction of both sestamibi and
etrofosmin, the technetium-99m–labeled perfusion
gents have a shorter effective half-life and lower
ffective dose equivalent (12.3 mSv/1,480 MBq and
.6 mSv/1,480 MBq, respectively) than thallium-
01, allowing administration of much larger doses,
esulting in “prettier” images. Hence, the techne-
ium agents were used for 90% of the 8 million
ardiac imaging studies in the U.S. (9) in 2006.
lthough some institutions adopted a dual tracer
maging protocol as a means of shortening the
1-day imaging protocol,” where thallium-201 was
mployed for the rest images and a technetium-
9m–labeled agent for stress (10), this approach did
ot take advantage of the major virtue of thallium as
stress imaging agent. In the past, investigators,
uch as Steele et al. (11), attempted to perform dual
racer imaging with injection of thallium-201 at
tress [148 MBq] and technetium-99m sestamibi at
est [222 MBq]. These investigators used a unique
ulti-aperture pinhole collimator mounted on a
ultidetector Anger camera to record single-
hoton emission computed tomography (SPECT)
mages, and relied on novel software to minimize
catter in their reconstructed data. Although the
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284results were promising, their approach employed a
4-mCi dose of thallium-201.
Berman et al. (12), in their article in this issue of
iJACC, use a new high-speed SPECT, coupled with
a reduced dose of thallium-201 administered at
stress, in a novel approach to regain the virtues of
thallium-201 as a tracer for stress myocardial per-
fusion imaging, while minimizing the radiation
burden. The authors report that doses of 2 mCi (74
MBq) of thallium-201 injected at stress and a
6-min image acquisition protocol produced images
of good-to-excellent diagnostic quality in up to 97%
of patients. The authors indicate that after record-
ing the stress thallium images, a dose of 8.9 mCi
(396 MBq) of technetium-99m–labeled sestamibi
or tetrofosmin and a 4-min imaging protocol pro-
vided diagnostic quality images in approximately
96% of patients at rest.
The high-speed SPECT instrument offers the
potential of simultaneous recording of dual tracer
images. The solid state detector material, cadmium
zinc telluride (CZT), has a spectral resolution of
6.5% at 140 keV (13). Simultaneous dual tracer
imaging would minimize problems detecting small
changes in regional perfusion and likely allow easier
identification of attenuation artifacts.
Although the 6.35 mm (1/4 inch) or 9.52 mm
(3/8 inch) sodium-iodide detectors used in modern
Anger cameras have spectral resolution of approxi-
mately 10% at 140 keV and 15% at 80 keV, (far
worse than CZT), it might be possible to use Dr.
Berman’s concept to record dual tracer images with
these instruments. Back of the envelope consider-
ations suggest that using a combination of asym-
metrical windows and scatter correction algorithms
with administration of 3 mCi (110 MBq) thallium-
201 at stress and 10 mCi (370 MBq) of a techne-
tium agent at rest might produce SPECT images ofhexakis 2-methoxy-2-isobutyl isonitrile Available at: httptempted to do this (14) albeit with only modest
success. However, the lower energy Tl-201 window
data are substantially contaminated by the down-
scatter from the higher (3 to 4 times greater)
injected dose of the technetium-99m (Tc-99m)
agent. Improved energy resolution does not assist
much in this situation, because: 1) the origin of the
scattered events is within the body; and 2) as the
lower Tl-201 window measures a broad spectrum of
X-rays with photon energies of 70 to 80 keV, the
window is a reasonably wide one. Experience from
previous work using Tc-99m and measuring Gd-
153 transmission photons (window centered at 100
keV) showed that, in the thorax, the down-
scattered photon count rate could be as high as 60%
of that recorded in the 140 keV photopeak window
(15). Similar amounts could be expected in the 70-
to 80-keV window. Thus, trying to detect areas of
decreased perfusion in the stress Tl-201 study will
be particularly susceptible to the ability to accurately
correct for the down-scattered Tc-99m photons.
Even if dual tracer simultaneous imaging is not
feasible, the present proposal makes a major con-
tribution with the documentation that sequential
images of diagnostic quality images can be recorded
in 6 min with an administered dose of 2 mCi of
thallium-201 at stress and a subsequent 4-min
image after injection of 8 to 9 mCi of a technetium
perfusion agent at rest.
We look forward to future publications docu-
menting the sensitivity and specificity of these novel
imaging protocols in patients undergoing selective
coronary angiography or CT coronary angiography.
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